Related Experiment Video

Updated: Jul 15, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

MDM2 and MDM4: p53 regulators as targets in anticancer therapy

Franck Toledo1, Geoffrey M Wahl

  • 1Institut Curie, Centre de Recherche, UMR CNRS 7147, 26 rue d'Ulm, 75728 Paris Cedex 05, France. franck.toledo@curie.fr

The International Journal of Biochemistry & Cell Biology
|May 15, 2007
PubMed

Insights

Reactivating the tumor suppressor p53 is a promising cancer therapy. Inhibitors MDM2 and MDM4, which inactivate p53, can be targeted. Combined MDM2 and MDM4 inhibition shows potential for effective anti-tumor activity.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • The TP53 gene, encoding the p53 tumor suppressor protein, is frequently altered in human cancers.
  • p53 inactivation in cancer can occur through overexpression of its inhibitors, MDM2 and MDM4 (also known as MDMX).
  • Tumors with wild-type p53 and MDM2/MDM4 overexpression present an opportunity for p53 reactivation therapies.

Purpose of the Study:

  • To review recent findings on MDM2 and MDM4 regulatory roles.
  • To discuss implications for developing novel p53-based anticancer strategies.
  • To explore the potential of targeting MDM2 and MDM4 for cancer treatment.

Main Methods:

  • Literature review of recent insights into MDM2 and MDM4 functions.
  • Analysis of distinct and complementary mechanisms by which MDM2 and MDM4 inhibit p53.
  • Evaluation of p53 stabilization and activation pathways.

Main Results:

  • MDM4 primarily regulates p53 activity, while MDM2 mainly controls p53 stability.
  • MDM2-dependent degradation of MDM2 and MDM4 contributes to p53 stabilization and activation after DNA damage.
  • Combined antagonism of MDM2 and MDM4 is suggested to be more effective than targeting MDM2 alone.

Conclusions:

  • Targeting MDM2 and MDM4 offers a promising therapeutic avenue for cancers with wild-type p53.
  • Simultaneous inhibition of MDM2 and MDM4 may lead to enhanced p53 activation and potent anti-tumor effects.
  • Future anticancer strategies should consider combination therapies targeting both MDM2 and MDM4.

More Related Videos

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay05:17

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...